Merrimack Pharmaceuticals (MACK)

Revenue in 2024 (TTM): N/A

In 2023 the company made a revenue of N/A a decrease over the revenue in the year 2022 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Merrimack Pharmaceuticals from 2010 to 2024

Annual revenue

Year	Revenue	Change
2024 (TTM)	N/A
2023	N/A
2022	N/A
2021	N/A
2020	N/A
2019	N/A
2018	N/A
2017	N/A	-100%
2016	NZ$88.4 M	-32.21%
2015	NZ$0.13 B	-0.56%
2014	NZ$0.13 B	125.53%
2013	NZ$58.15 M	-2.22%
2012	NZ$59.46 M	35.65%
2011	NZ$43.83 M	66.57%
2010	NZ$26.31 M

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Sanofi SNY	NZ$94.61 B	N/A	🇫🇷 France
AVEO Oncology AVEO	NZ$0.16 B	N/A	🇺🇸 USA
Geron GERN	NZ$52.12 M	N/A	🇺🇸 USA
Clovis Oncology CLVS	NZ$0.23 B	N/A	🇺🇸 USA
Eterna Therapeutics ERNA	NZ$1.05 M	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for Merrimack Pharmaceuticals (MACK)

Revenue in 2024 (TTM): N/A